GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in GRI Bio, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- +1 vs. Q3 2021
- Shares held
- 479.0K
- +100.5K (+26.5%) vs. Q3 2021
- Total value
- $2.86M
- +$113.0K (+4.1%) vs. Q3 2021
- New holders
- 3
- 2 more added
- Sold out
- 2
- 3 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GRI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $164.7K |
| Q1 2026 | 6 | $64.7K |
| Q4 2025 | 7 | $14.7K |
| Q3 2025 | 8 | $276.8K |
| Q2 2025 | 5 | $25.3K |
| Q1 2025 | 5 | $15.5K |
| Q4 2024 | 8 | $185.2K |
| Q3 2024 | 7 | $49.7K |
| Q2 2024 | 5 | $139.7K |
| Q1 2024 | 6 | $177.2K |
| Q4 2023 | 9 | $82.8K |
| Q3 2023 | 6 | $887.2K |
| Q2 2023 | 5 | $5.09M |
| Q1 2023 | 9 | $37.4K |
| Q4 2022 | 13 | $88.5K |
| Q3 2022 | 8 | $74.0K |
| Q2 2022 | 10 | $141.0K |
| Q1 2022 | 13 | $765.0K |
| Q4 2021 | 13 | $2.86M |
| Q3 2021 | 12 | $2.75M |
| Q2 2021 | 11 | $3.15M |
| Q1 2021 | 10 | $2.44M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding GRI Bio, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 198,085 | $1.18M | 0.34% | 00.0% | Unchanged |
| Vanguard Group Inc | 164,923 | $986.0K | 0.00% | +164,923 | New |
| Boothbay Fund Management, LLC | 21,250 | $127.0K | 0.00% | 00.0% | Unchanged |
| Laidlaw Wealth Management LLC | 20,200 | $121.0K | 0.02% | +20,200 | New |
| Envestnet Asset Management Inc | 18,465 | $110.0K | 0.00% | +1,592+9.4% | Added |
| Geode Capital Management, LLC | 17,841 | $106.0K | 0.00% | −6,293−26.1% | Reduced |
| Zeke Capital Advisors, LLC | 15,000 | $90.0K | 0.01% | −5,000−25.0% | Reduced |
| State Street Corp | 11,200 | $67.0K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 5,533 | $33.0K | 0.00% | −1,357−19.7% | Reduced |
| UBS Group AG | 2,761 | $17.0K | 0.00% | +1,263+84.3% | Added |
| Morgan Stanley | 2,628 | $16.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,075 | $6.00K | 0.00% | +1,075 | New |
| Wells Fargo & Company | 14 | $0 | 0.00% | 00.0% | Unchanged |
| Murchinson Ltd. | 0 | $0 | 0.00% | −74,935−100.0% | Sold out |
| Total Clarity Wealth Management, Inc. | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |